Hamdan Medical Journal

STATE-OF-THE-ART REVIEW
Year
: 2016  |  Volume : 9  |  Issue : 1  |  Page : 39--56

Novel systemic therapy in advanced non-small-cell lung cancer


Cristina Tiut1, Christoph C Zielinski2 
1 Department of Medical Oncology, Gral Medical, Bucharest, Romania, Medical University Vienna International, Vienna, Austria
2 Clinical Division of Oncology, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna and General Hospital, Vienna, Austria

Correspondence Address:
Christoph C Zielinski
Department of Medicine I, Medical University Vienna, Währinger Gürtel 18–20, 1090, Vienna
Austria

Standard chemotherapy regimes (platinum-based combinations) for advanced non-small-cell lung cancer have reached their therapeutic limits. In the last few years standard chemotherapy has been supplemented by targeted therapy. Targeted therapy consists of tyrosine kinase inhibitors (TKIs) against epidermal growth factor receptor (EGFR) mutation-positive tumours or ALK (anaplastic lymphoma kinase)-rearranged tumours as well as antiangiogenic TKIs and monoclonal antibodies directed against vascular endothelial growth factor, vascular endothelial growth factor receptor 2 or EGFR. Although targeted therapy has made remarkable progress, there is great hope for the use of immune checkpoint inhibitors, which specifically enhance the immune response directed against the tumour.


How to cite this article:
Tiut C, Zielinski CC. Novel systemic therapy in advanced non-small-cell lung cancer.Hamdan Med J 2016;9:39-56


How to cite this URL:
Tiut C, Zielinski CC. Novel systemic therapy in advanced non-small-cell lung cancer. Hamdan Med J [serial online] 2016 [cited 2020 Oct 25 ];9:39-56
Available from: http://www.hamdanjournal.org/article.asp?issn=2227-2437;year=2016;volume=9;issue=1;spage=39;epage=56;aulast=Tiut;type=0